Summary Forty-six previously untreated patients with advanced ovarian cancer were treated with combination chemotherapy comprising cisplatin 80mgm 2 i.v. and cyclophosphamide 1 gm-2 i.v. every 28 days for 5 cycles. Eighty-five percent of patients received more than 75% of the calculated doses, and of 43 evaluable patients, a complete response was achieved in 31 (72%), a partial response in 4 (9.3%) and 8 patients had static or progressive disease. The actuarial survival of the whole group is 60% at a median follow-up of 2 years. Twenty-four patients in complete clinical or pathological remission were then treated with whole abdominal radiotherapy 2,500cGy followed by a pelvic boost of 2,000cGy. The pelvic boost was omitted in 3 patients, and the overall radiotherapy treatment time extended in a further 4 patients on account of myelosuppression. The actuarial survival of the 24 patients receiving both treatments at a median of 30 months follow-up is 75%. In the 10 patients with negative second-look procedures completing both treatments there have been no tumour related deaths at a median follow-up of 33 months.
Ovarian cancer shows a rising incidence in Western Europe and the USA, and is the 4th commonest cause of death from cancer in women (Muir & Nectouse, 1978) . The development and assessment of treatment approaches has been impaired by variations in staging methods which have altered the distribution of cases between FIGO stages I-IV over the last 10 years; however, ovarian cancer remains a disease of the abdomen in over 80% of cases. The extent of primary surgical debulking is an important prognostic factor (Griffiths et al., 1979; Hacker et al., 1983) , but where the disease is advanced chemotherapy is required in addition. For many years alkylating agents were used alone giving response rates ranging from 10 to 65% and a response duration of the order of 12 months (Young, 1979) , but no clear prolongation of survival (Richardson et al., 1985a,b) .
When cisplatin is incorporated in combination chemotherapy schedules, response rates of the order of 70% have been achieved (Green & Young, 1983; Richardson et al., 1985a,b) and there is now evidence of a modest improvement of survival (Dembo, 1986) . The highest recorded response rate (92%) and a median survival in excess of 2 years have been reported using the four drugs cyclophosphamide, hexamethylmelamine, adriamycin and cisplatin (CHAP) (Neijt et al., 1984) . However, the .toxicity of this regime was severe and two randomised trials have shown that the combination of cisplatin and cyclophosphamide gives equivalent progression-free survival and overall survival with much reduced toxicity (Edmonson et al., 1985; Neijt et al., 1985) .
The place of radiotherapy has proved harder to define, but the beneficial effect seems confined to small volume disease as reported by Dembo & Bush (1983) who showed a 78% 6-year survival in stages Ib, II and 'asymptomatic' stage III patients with abdominal and pelvic irradiation, and Smith et al. (1975) and Martinez et al. (1985) also showed that irradiation was associated with prolonged survival in stages 1-111 patients. Histopathology, age and residual disease volume were important prognostic factors. However, the staging criteria used in these studies were inadequate by present day standards, and there was a high rate of relapse outside the pelvis. Hainsworth et al. (1983) found abdominopelvic irradiation after chemotherapy to be poorly tolerated, and only 7 out of 17 patients completed the planned course principally because of myelosuppression. In other small series employing a variety of cytotoxic drug combinations, the treatment which could be administered was limited by myelosuppression and bowel toxicity (Steiner et al., 1985; Hacker et al., 1985; Rizel et al., 1985; Greiner et al., 1984) .
In the present study patients were treated with five cycles of the two most active drugs, cyclophosphamide and cisplatin, to achieve a complete remission followed in patients with absence of macroscopic residual disease by radiotherapy to the whole abdomen and pelvis given in small fractions. Consolidation radiation therapy was therefore employed at the optimum time when residual tumour volume was small (Tubiana, 1983) .
Patients and methods
Forty-six patients were treated between July 1983 and February 1985 and their characteristics are shown in Table I . All patients had histologically proven epithelial tumour, and patients with 'borderline' malignancy were not eligible.
Exclusion criteria were -age over 70yrs, ischaemic heart disease, other malignancy and performance status (WHO) 3 or 4.
Chemotherapy
The combination chemotherapy regime consisted of cisplatin 80mgm 2 infused over 1 h and cyclophosphamide 1 gm-2 i.v. as a bolus. Pre-and post-hydration was given to achieve a minimum urine output of 200mlh-1 to minimize renal damage. Creatinine clearance, serum magnesium and blood counts were monitored, and treatment was administered at 4 weekly intervals to a total of 5 courses.
Radiotherapy
Radiotherapy was given to the whole abdomen including the diaphragm using parallel opposed fields to a mid plane dose of 2,500cGy in 25 fractions to patients who were in complete clinical or pathological remission. All patients were Subset analysis Twenty-four patients in complete clinical or pathological complete remission proceeded to whole abdominopelvic irradiation. Three further patients with static disease (1 patient) and partial response (2 patients) were also given abdominopelvic irradiation at full dose and died 8, 7 and 6 months later, respectively. Three patients have refused radiotherapy.
Of these 24 patients the actuarial disease free survival at 30 months was 75% (Figure 2) , there being 4 deaths at 14, 20, 29 and 30 months. All three relapses were in both the abdomen and pelvis, and the fourth patient had the cachexia and extensive intra-abdominal fibrosis referred to above, with no tumour found at laparotomy just before death. This patient, who presented with Stage IV disease, was the only one out of 10 patients with negative second-look procedures completing abdominopelvic radiotherapy who has died at a median follow-up of 33 moderate or poor histological differentiation, the actuarial survival at 2 years was 67% (Figure 3) . The 4 patients in whom gross disease more than 10cm in diameter was present at the start of chemotherapy were all dead within 12 months, but there was no significant difference in actuarial survival betWeen those debulked to <5cm and those debulked to <2cm maximum tumour diameter, although the risk of relapse increased progressively with FIGO stage and pre-chemotherapy residual disease (Table II) . Out of 223 cycles of chemotherapy, the total leucocyte count fell below 1 .0 x 109 1 1 in 10 patients (4.5% of cycles) and a fall below 2.0 x 109 1 -1 was recorded in a further 30 patients (13.5% of cycles). There were transfusions given to 12 patients and no episodes of neutropenic fever. The creatinine clearance fell below 50ml min-in 6 patients, and this nephrotoxicity was cumulative, reaching a peak incidence after cycle 4.
Four patients discontinued chemotherapy after the fourth cycle. The radiotherapy was well tolerated by the patients although myelosuppression was seen in most cases. A rapid fall in the total WBC in the first week to around 2 x 109 1-1 was usually seen, but in most cases it was possible to continue radiotherapy without this fall continuing. Suspension of treatment for two or more weeks was required on account of myelosuppression in tive other patients, but in only one of these was treatment discontinued and the pelvic boost omitted on account of thrombocytopenia. The median number of treatment days delayed was 12 (mean 11.2 days, range 9-25 days). There were no episodes of neutropenic fever or bleeding, but one case of WHO Grade III late renal damage, a second of Grade III elevated liver function tests and a third of Grade III gastrointestinal toxicity were recorded. In one case a recto-vaginal fistula developed following abdominal irradiation, and the pelvic boost was omitted. One further patient had extensive intraperitoneal fibrosis as discussed above.
Discussion
We have shown that a regime consisting of aggressive chemotherapy comprising cisplatin and cyclophosphamide followed by a tumoricidal dose of radiation to the abdomen and pelvis can be tolerated by a high proportion of middleaged women with carcinoma of the ovary. Myelosuppression was acceptable during both the chemotherapy and radiotherapy components of treatment. The relative lack of toxicity seen with the radiation therapy may be related in part to the absence of adriamycin from the induction regime.
These results show a complete response rate to chemotherapy of 72% which compares favourably with other published regimes. It has been estimated that cisplatin containing combinations prolong the median survival time in advanced ovarian cancer by 6-12 months over those who have never received cisplatin or its analogues (Dembo, 1986) , although there is still controversy over the size of the effect. This survival benefit of chemotherapy has been particularly marked in those patients with disease debulked to a maximum residual diameter of 3 cm or less (Ozols & Young, 1984) and it is at this volume that the dose of achievable radiation therapy reaches its optimum (Tubiana, 1983) , as the number of residual clonogenic cells is low.
In the present study the 24 patients in complete remission given combined modality treatment (Figure 2 ) provide evidence that the combined approach of chemotherapy and radiotherapy may have produced a significant cohort of long term survivors, the only death being associated with extensive peritoneal fibrosis with no evidence of recurrent tumour. This is emphasised by the subset analyses of the 10 patients in pathological complete remission, and in the poor risk intra-abdominal disease patients (Figure 3) given both treatments. A negative second-look procedure confirms the first requirement has been met for a treatment approach designed to achieve prolonged survival, but almost certainly further consolidation chemotherapy or radiation therapy is required to improve the long term results in this disease (Sutton et al., 1986; Cain et al., 1986) . In the 3 patients given abdominopelvic radiotherapy where macroscopic disease was present, the short survival would indicate this treatment was of little benefit in this group.
The lack of an effect of moderate tumour bulk on survival either at presentation or after surgery may be further evidence that the irradiation is providing a consolidation effect to the chemotherapy, as in previous studies with surgery and chemotherapy alone, bulk has been an important variable in determining outcome (Williams et al., 1982) . However, the 9 patients with stage IV disease have shown a particularly poor survival, as did those 4 in whom no debulking was possible, and in the entire group FIGO stage and residual disease were related to relapse. It may be that the critical site of tumour (e.g. in bowel wall or liver) is more important than bulk: alternatively this intensive treatment approach has overcome an adverse factor applicable only to these earlier studies.
The present series compares favourably in outcome to other studies of sequential chemotherapy and radiotherapy. Hainsworth et al. (1983) found that 15 out of 17 patients given sub-optimal doses of chemotherapy and radiotherapy relapsed within a median of 8 months. Rustin et al. (1987) employed a similar approach, but omitted the boost to the pelvis, and in 27 patients with Stage III disease, 8 of whom were in pathological complete remission, found a median progression free survival of 19 months. In the present study the restriction of the 2 drug combination to 5 cycles and the low fraction size of radiotherapy may have contributed to the improved results.
This aggressive approach deserves further evaluation in adequately debulked patients without visceral involvement. It is clear that the selection of an adequate dose and schedule of chemotherapy (Piccart et al., 1987) and of radiation therapy (Dembo et al., 1979 ) is vital to achieve disease control without excessive toxicity. However, one third of patients may not reach this stage of treatment on account of failure to achieve response to chemotherapy or refusal of patients to accept the complete course of intensive treatment. Patients with poor prognostic factors, such as Stage IV disease, require more intensive induction chemotherapy. In those patients responding to chemotherapy the abdominopelvic radiotherapy given in the present study needs to be compared in a randomised trial to continuing chemotherapy or no further therapy.
